4.6 Article

Cox15 is a novel oncogene that required for lung cancer cell proliferation

Journal

Publisher

ACADEMIC PRESS INC ELSEVIER SCIENCE
DOI: 10.1016/j.bbrc.2021.09.010

Keywords

Lung cancer; Cox15; Aripiprazole; Biomarker; Targeted therapy

Funding

  1. Health Commission of Yunnan Province Training plan for Medical Reserve Talents [H-2017029]
  2. Research Innovation team of Yunnan province [2019HC022]
  3. Yunnan clinical medical center of nervous system diseases [ZX2019-03-05]

Ask authors/readers for more resources

The study reveals the important role of Cox15 in lung cancer and its potential as a prognostic marker for lung cancer patients in the future.
Lung cancer is one of the most malignant and prevalent tumors and accounts for the vast majority of cancer death worldwide. However, the molecular mechanisms underlying lung cancer progression are poorly understood. Here, we reveal that both transcription and protein expression levels of Cox15 were increased in lung cancer. Nrf2 specifically binds to the Cox15 promoter and triggers Cox15 expression at the transcriptional level. Cox15 functions as a novel oncogene that facilitates lung cancer cell proliferation. Additionally, Aripiprazole, a potent inhibitor of Cox15, executives profoundly suppressive effects on lung cancers cells growth and tumor progression in vivo and in vitro through exerting therapeutic effects. Taken together, our results unravel that Cox15 holds great potential to act as a prognostic molecule for lung cancer patients' prognosis in the future. (c) 2021 Published by Elsevier Inc.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available